Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
-
Published:2023-11-02
Issue:1
Volume:15
Page:
-
ISSN:1758-9193
-
Container-title:Alzheimer's Research & Therapy
-
language:en
-
Short-container-title:Alz Res Therapy
Author:
Bader Ilse,Bader Ilona,Lopes Alves Isadora,Vállez García David,Vellas Bruno,Dubois Bruno,Boada Mercè,Marquié Marta,Altomare Daniele,Scheltens Philip,Vandenberghe Rik,Hanseeuw Bernard,Schöll Michael,Frisoni Giovanni B.,Jessen Frank,Nordberg Agneta,Kivipelto Miia,Ritchie Craig W.,Grau-Rivera Oriol,Molinuevo José Luis,Ford Lisa,Stephens Andrew,Gismondi Rossella,Gispert Juan Domingo,Farrar Gill,Barkhof Frederik,Visser Pieter Jelle,Collij Lyduine E.,
Abstract
Abstract
Background
The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, potential enrollment barriers in the pre-dementia population are relatively under-reported. In a large European longitudinal biomarker study (the AMYPAD-PNHS), we investigated main enrollment barriers in individuals with no or mild symptoms recruited from research and clinical parent cohorts (PCs) of ongoing observational studies.
Methods
Logistic regression was used to predict study refusal based on sex, age, education, global cognition (MMSE), family history of dementia, and number of prior study visits. Study refusal rates and categorized enrollment barriers were compared between PCs using chi-squared tests.
Results
535/1856 (28.8%) of the participants recruited from ongoing studies declined participation in the AMYPAD-PNHS. Only for participants recruited from clinical PCs (n = 243), a higher MMSE-score (β = − 0.22, OR = 0.80, p < .05), more prior study visits (β = − 0.93, OR = 0.40, p < .001), and positive family history of dementia (β = 2.08, OR = 8.02, p < .01) resulted in lower odds on study refusal. General study burden was the main enrollment barrier (36.1%), followed by amyloid-PET related burden (PCresearch = 27.4%, PCclinical = 9.0%, X2 = 10.56, p = .001), and loss of research interest (PCclinical = 46.3%, PCresearch = 16.5%, X2 = 32.34, p < .001).
Conclusions
The enrollment rate for the AMYPAD-PNHS was relatively high, suggesting an advantage of recruitment via ongoing studies. In this observational cohort, study burden reduction and tailored strategies may potentially improve participant enrollment into trial readiness cohorts such as for phase-3 early anti-amyloid intervention trials.
The AMYPAD-PNHS (EudraCT: 2018–002277-22) was approved by the ethical review board of the VU Medical Center (VUmc) as the Sponsor site and in every affiliated site.
Publisher
Springer Science and Business Media LLC
Subject
Cognitive Neuroscience,Neurology (clinical),Neurology
Reference58 articles.
1. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. 2. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frolich L, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60. 3. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29. 4. Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022;18:389–99. 5. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33–cm33.
|
|